T2D: Impact of Vision and Hearing Impairments on CV Risk Outcomes  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
Can't see the images?View as webpage .
 
To ensure that you never miss an issue, pleasewhitelist us.
HDR_DIC_NL_KO
DIC_23Years_Badge.png
     

DPP-4 Inhibitors Vs. Sulphonylureas As Add-On to Metformin – Assessing CV Outcomes in Type 2 Diabetes

READ ABOUT DPP-4 INHIBITORS VS. SULPHONYLUREAS AND ASSESSING CV OUTCOMES IN T2D
New retrospective study results compare the two most largely prescribed antidiabetic medication classes in addition to metformin, to determine the impact on the incidence of CV events in patients with T2DM. 
Get Findings

Type 2 Diabetes: The Impact of Vision and Hearing Impairments on CV Risk Outcomes and Mortality

A comprehensive study reveals the importance of ophthalmologic and otologic care in patients with T2DM due to the association of increased risks for cardiovascular events in those with a decline in vision and hearing abilities. 
 
Read More
T2D - THE IMPACT OF VISION AND HEARING IMPAIRMENTS ON CV RISK OUTCOMES AND MORTALITY - CLICK HERE TO SEE MORE

LEARN ABOUT HEALTH DISPARITIES AMONG PEOPLE WITH DIABETES IN US AND RELATIONSHIP OF RACE, ECONOMIC STATUS, AND ETHNICITY CONTRIBUTING TO HEALTH INEQUALITY
Health Disparities among People with Diabetes in U.S. and Relationship of Race, Economic Status, and Ethnicity Contributing to Health Inequality

Research results show that race, ethnicity, and socio-economic disparity influence the uptake of GLP-1 RA medication among people with diabetes which suggests that they are critical determinants of health. 
 
Learn More

     

  dic_icon_facebook  dic_icon_twitter   dic_icon_linkedIn

©2022 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control

2093 Philadelphia Pike #8370
Claymont, DE 19703

DiabetesInControl.com | Contact Us |  Update Profile | Unsubscribe